According to Zacks, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts. “
TSRO has been the subject of a number of other research reports. Bank of America Corp. assumed coverage on shares of Tesaro in a report on Tuesday, August 30th. They issued a neutral rating and a $97.00 price target for the company. FBR & Co raised their price target on shares of Tesaro from $102.00 to $115.00 and gave the stock an outperform rating in a report on Monday. Citigroup Inc. raised their price target on shares of Tesaro from $90.00 to $120.00 and gave the stock a buy rating in a report on Monday, August 8th. Mizuho lifted their target price on shares of Tesaro from $67.00 to $94.00 and gave the company a buy rating in a research report on Tuesday, July 5th. Finally, Robert W. Baird assumed coverage on shares of Tesaro in a research note on Monday, July 18th. They issued an outperform rating and a $105.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus target price of $110.11.
Shares of Tesaro (NASDAQ:TSRO) opened at 116.15 on Tuesday. The stock’s 50 day moving average is $98.99 and its 200-day moving average is $70.75. Tesaro has a 12 month low of $29.51 and a 12 month high of $122.89. The company’s market cap is $5.97 billion.
Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The firm had revenue of $36.60 million for the quarter, compared to the consensus estimate of $4.98 million. During the same period last year, the firm earned ($1.51) earnings per share. On average, equities analysts forecast that Tesaro will post ($7.36) EPS for the current year.
In related news, SVP Martin H. Jr. Huber sold 408 shares of Tesaro stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total value of $44,112.96. Following the completion of the transaction, the senior vice president now owns 1,250 shares in the company, valued at $135,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jeffrey H. Hanke sold 29,166 shares of Tesaro stock in a transaction that occurred on Tuesday, August 30th. The shares were sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the completion of the transaction, the vice president now owns 29,166 shares of the company’s stock, valued at approximately $2,509,442.64. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Tesaro by 9.6% in the second quarter. FMR LLC now owns 6,097,449 shares of the biopharmaceutical company’s stock worth $512,490,000 after buying an additional 531,892 shares during the period. Vanguard Group Inc. boosted its position in shares of Tesaro by 11.0% in the second quarter. Vanguard Group Inc. now owns 2,216,739 shares of the biopharmaceutical company’s stock worth $186,317,000 after buying an additional 219,902 shares during the period. BlackRock Fund Advisors boosted its position in shares of Tesaro by 8.2% in the second quarter. BlackRock Fund Advisors now owns 1,399,709 shares of the biopharmaceutical company’s stock worth $117,646,000 after buying an additional 105,803 shares during the period. State Street Corp boosted its position in shares of Tesaro by 12.9% in the second quarter. State Street Corp now owns 1,008,667 shares of the biopharmaceutical company’s stock worth $84,777,000 after buying an additional 114,918 shares during the period. Finally, Passport Capital LLC acquired a new position in shares of Tesaro during the second quarter worth $61,720,000. Hedge funds and other institutional investors own 88.81% of the company’s stock.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related companies with MarketBeat.com's FREE daily email newsletter.